Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is positioned favorably in the biopharmaceutical sector, focusing on significant unmet medical needs in oncology and COVID-19 treatment. The company's development of innovative therapeutics, specifically the promising drug Endoxifen for breast cancer and two novel COVID-19 therapies, underscores its potential for substantial growth. Positive valuation metrics highlighted by recent net present value (NPV) analyses indicate an attractive valuation, bolstered by the potential for key clinical milestones to act as catalysts for enhancing stock performance.

Bears say

Atossa Therapeutics reported a net loss of $8.7 million, or an earnings per share (EPS) of $(0.07), consistently missing consensus estimates, which reflects ongoing financial instability and challenges in managing operational costs. The company's reliance on the success of its clinical candidates, including Endoxifen for breast cancer and its COVID-19 treatments, presents significant risks, particularly concerning their ability to demonstrate safety and efficacy in clinical trials. Additionally, factors such as potential regulatory hurdles, commercialization challenges, and broader economic conditions could impede revenue generation, further heightening the negative outlook regarding the company's financial health and stock performance.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.